Fatal pulmonary hemorrhage occurred on the eighth day of moxalactam therapy. No other pharmacologic agent or obvious cause could be attributed to the hemoptysis. Moxalactam-induced pulmonary hemorrhage should be included in the differential diagnosis of an infiltrate when moxalactam is being administered.